No abstract

No abstract

BACKGROUND:The aim of this study was to determine mortality rates and to evaluate clinical features of coronavirus disease 2019 (COVID-19) patients with septic shock in intensive care unit (ICU). MATERIALS AND METHODS:The medical records of COVID-19 patients requiring ICU admission were retrospectively reviewed over a 3-month period. RESULTS:Forty patients with COVID-19 admitted to the ICU were screened. Two patients died within 24 h after ICU admission. After these patients were excluded, septic shock was detected in 11 (28%) of 38 patients during the 30-day follow-up period. Ten (91%) of the 11 patients with septic shock died in the ICU. Eight (72%) of the 11 patients had nosocomial infection during 30-day follow-up period. Six (54%) of 11 septic shock patients had positive culture results for bacterial pneumonia on the day of septic shock. The median time from symptom onset to septic shock was 14 (5-34) days. The median duration from ICU admission until septic shock was 8 (1-28) days. All of the patients with septic shock underwent invasive mechanical ventilation (IMV).CONCLUSION: COVID-19 patients with septic shock have higher mortality rates, percentage of nosocomial infection, and IMV requirement.

Approximately 5-10% of coronavirus disease-19 (COVID-19) patients need intensive care and respiratory support [1] and, among those who develop pneumonia, 14% need oxygen therapy due to severe respiratory failure, and 5% need mechanical ventilation [2]. The disease severity increases in patients with comorbidities, especially advanced age and hypertension [3].Convalescent plasma therapy is classical adoptive immunotherapy. It has been used to treat SARS, MERS, and the 2009 H1N1 outbreak in the last two decades [4][5][6][7]. For this reason, it has been proposed as an adjunct treatment for COVID-19. It is thought that antibodies in the plasma obtained from recovered patients will reduce the virus load, thus limiting the severity of the disease [8].In April 2020, some early reports indicated that, in PCR-confirmed COVID-19, convalescent plasma may result in a decrease in oxygen demand within three days, a decrease in CRP levels, and an improvement in chest radiography within the first week [9,10]. However, in large-scale randomised con-